Free tool
Stocks listed on Nasdaq GM
We cover 65 companies listed on Nasdaq GM. The median market value in the group is $3.34B. Across the group, the median move over the past trading day is +1.05%. 72% of the 64 with a 200-day average trade above it. Price change over the past year runs from −42.3% to +269.2% across the middle 80 percent of the group, with a median of +38.0%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
65 of 701 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +67.40% |
| AAOI | Applied Optoelectronics, Inc. Common Stock | $9.61B | Mid cap | +364.87% |
| APPF | AppFolio, Inc. | $7.90B | Mid cap | −18.83% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +14.26% |
| CAMT | Camtek Ltd. | $6.84B | Mid cap | +77.60% |
| ORKA | Oruka Therapeutics, Inc. | $6.74B | Mid cap | +601.72% |
| MAAS | Maase Inc. | $6.63B | Mid cap | +271.41% |
| GDS | GDS Holdings Limited | $6.61B | Mid cap | −0.66% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +79.61% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +138.24% |
| TTD | The Trade Desk, Inc. | $6.23B | Mid cap | −74.70% |
| TVTX | Travere Therapeutics, Inc. | $6.06B | Mid cap | +288.91% |
| RDNT | RadNet, Inc. | $6.05B | Mid cap | +10.45% |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +36.58% |
| CRSP | CRISPR Therapeutics AG | $5.89B | Mid cap | +12.51% |
| XENE | Xenon Pharmaceuticals Inc. | $5.85B | Mid cap | +58.42% |
| LGND | Ligand Pharmaceuticals Incorporated | $5.62B | Mid cap | +77.42% |
| ACMR | ACM Research, Inc. | $5.56B | Mid cap | +176.98% |
| RUM | RUM Group Inc. | $5.07B | Mid cap | +35.32% |
| ENPH | Enphase Energy, Inc. | $4.92B | Mid cap | −2.30% |
| USAR | USA Rare Earth, Inc. | $4.75B | Mid cap | +22.62% |
| OLLI | Ollie's Bargain Outlet Holdings, Inc. | $4.51B | Mid cap | −42.68% |
| RLAY | Relay Therapeutics, Inc. | $4.51B | Mid cap | +486.04% |
| DAVE | Dave Inc. | $4.46B | Mid cap | +76.49% |
| TNGX | Tango Therapeutics, Inc. | $4.13B | Mid cap | +264.73% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +52.72% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.82B | Mid cap | +233.60% |
| FLY | Firefly Aerospace Inc. | $3.73B | Mid cap | −50.23% |
| FRPT | Freshpet, Inc. | $3.62B | Mid cap | +33.95% |
| GPCR | Structure Therapeutics Inc. | $3.56B | Mid cap | +168.82% |
| VCYT | Veracyte, Inc. Common Stock | $3.54B | Mid cap | +49.04% |
| NMIH | NMI Holdings Inc. Class A Common Stock | $3.41B | Mid cap | +14.39% |
| CSQ | Calamos Strategic Total Return Fund | $3.34B | Mid cap | +19.16% |
| NAMS | NewAmsterdam Pharma Company N.V. | $3.27B | Mid cap | +10.69% |
| NVTS | Navitas Semiconductor Corporation | $3.25B | Mid cap | +100.65% |
| TMDX | TransMedics Group, Inc. | $3.23B | Mid cap | −18.59% |
| IRON | Disc Medicine, Inc. | $3.16B | Mid cap | +38.71% |
| SOUN | SoundHound AI, Inc. | $3.13B | Mid cap | −41.78% |
| ZLAB | Zai Lab Limited | $2.94B | Mid cap | −23.10% |
| APPN | Appian Corporation | $2.84B | Mid cap | +35.97% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +56.96% |
| NRIX | Nurix Therapeutics, Inc. | $2.73B | Mid cap | +178.70% |
| LUNR | Intuitive Machines, Inc. | $2.66B | Mid cap | +87.36% |
| CDNA | CareDx, Inc. | $2.63B | Mid cap | +298.43% |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.62B | Mid cap | +2.09% |
| DJT | Trump Media & Technology Group Corp. | $2.61B | Mid cap | −45.41% |
| TRVI | Trevi Therapeutics, Inc. | $2.56B | Mid cap | +146.57% |
| VERA | Vera Therapeutics, Inc. | $2.54B | Mid cap | +65.32% |
| KOD | Kodiak Sciences Inc. | $2.48B | Mid cap | +316.68% |
| ATRC | AtriCure, Inc. | $2.48B | Mid cap | +28.65% |
| RAPP | Rapport Therapeutics, Inc. | $2.46B | Mid cap | +249.76% |
| EMAT | Evolution Metals & Technologies Corp. | $2.45B | Mid cap | −79.26% |
| FIVN | Five9, Inc. | $2.41B | Mid cap | +20.92% |
| PAYO | Payoneer Global Inc. | $2.41B | Mid cap | +4.87% |
| OCUL | Ocular Therapeutix, Inc. | $2.39B | Mid cap | −8.34% |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.27B | Mid cap | +4.09% |
| URGN | UroGen Pharma Ltd. | $2.27B | Mid cap | +150.59% |
| PLBL | Polibeli Group Ltd | $2.23B | Mid cap | −40.00% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.23B | Mid cap | +38.03% |
| VCEL | Vericel Corporation | $2.21B | Mid cap | +20.76% |
| VERX | Vertex, Inc. | $2.19B | Mid cap | −46.69% |
| XNCR | Xencor, Inc. Common Stock | $2.18B | Mid cap | +265.79% |
| KEEL | Keel Infrastructure Corp. | $2.17B | Mid cap | +183.06% |
| ADMA | ADMA Biologics, Inc. | $2.14B | Mid cap | −42.86% |
| PVLA | Palvella Therapeutics, Inc. | $2.14B | Mid cap | +195.71% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.